Tandem Diabetes Care (NASDAQ:TNDM) Releases Earnings Results, Beats Expectations By $0.15 EPS

Tandem Diabetes Care (NASDAQ:TNDM) released its earnings results on Thursday. The medical device company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.15, FiscalAI reports. The firm had revenue of $283.69 million during the quarter, compared to the consensus estimate of $265.85 million. Tandem Diabetes Care had a negative return on equity of 45.97% and a negative net margin of 6.08%. The company’s revenue was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.31) earnings per share.

Here are the key takeaways from Tandem Diabetes Care’s conference call:

• Q3 results were strong: worldwide revenue rose 14% to $284 million and pump shipments increased 12%, while gross margin reached 57% and adjusted EBITDA margin was 6%. Tandem maintained its 2026 sales guidance of $1.065 billion–$1.085 billion.
• Pharmacy adoption is progressing more slowly than expected, though formulary coverage reached about 50% and recurring supply economics exceeded baseline expectations. Tandem expects the transition to weigh on sales into 2027 and said mid- to high-single-digit revenue growth is a reasonable starting point for next year.
• International sales rose 26% to a record $93 million, supported by product launches and stronger direct-market performance. Tandem plans to expand direct operations to cover roughly half of its international installed base by the end of 2027.
• Product development could broaden Tandem’s market opportunity: Mobi Tubeless is in late-stage FDA review, with commercial availability targeted for the first half of 2027 if cleared. The company also plans to begin a pivotal trial of its fully closed-loop system by year-end 2026, with a potential launch in 2028.

Tandem Diabetes Care Stock Performance

Tandem Diabetes Care stock traded down $1.08 during midday trading on Friday, hitting $16.91. 5,879,270 shares of the company were exchanged, compared to its average volume of 2,236,256. The business has a fifty day simple moving average of $17.65 and a two-hundred day simple moving average of $18.88. The company has a debt-to-equity ratio of 4.62, a quick ratio of 2.65 and a current ratio of 3.18. The firm has a market capitalization of $1.18 billion, a PE ratio of -23.49 and a beta of 1.59. Tandem Diabetes Care has a fifty-two week low of $12.26 and a fifty-two week high of $29.65.

Insider Transactions at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Christopher J. Twomey sold 1,700 shares of the company’s stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total value of $32,555.00. Following the sale, the director owned 24,434 shares in the company, valued at approximately $467,911.10. This represents a 6.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.10% of the company’s stock.

Tandem Diabetes Care News Summary

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Third-quarter revenue was $283.7 million, up 13.8% year over year and above analyst expectations of $265.85 million. The loss of $0.10 per share was also narrower than the consensus loss of roughly $0.25. Gross margin improved to 57%, up 2.7 percentage points year over year. Tandem Diabetes Care Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Tandem forecast 2026 sales of $1.065 billion to $1.085 billion, providing investors with a full-year revenue outlook. Tandem outlines 2026 sales range as CEO transition is set
• Neutral Sentiment: Jeannette Bankes was named president and CEO, succeeding John Sheridan, who is expected to retire at the end of 2026. The planned handover offers continuity but adds a leadership transition for investors to monitor. Tandem names Jeannette Bankes CEO
• Neutral Sentiment: Analyst actions were mixed: Barclays raised its target from $18 to $20 but kept an Equal Weight rating, while Wells Fargo lowered its target from $27 to $25 and maintained Overweight. Both targets remain above the cited $16.91 share price. Barclays rating information Wells Fargo target revision
• Negative Sentiment: Despite improved results, Tandem remains loss-making, with a negative net margin. Continued losses could limit how much investors reward revenue and margin progress. Tandem reports third-quarter loss

Wall Street Analyst Weigh In

A number of research firms have issued reports on TNDM. William Blair initiated coverage on shares of Tandem Diabetes Care in a research report on Friday, August 21st. They set an “outperform” rating for the company. Oppenheimer reiterated an “outperform” rating on shares of Tandem Diabetes Care in a research note on Friday, August 7th. Mizuho set a $20.00 price objective on shares of Tandem Diabetes Care in a research note on Friday. Truist Financial reduced their target price on shares of Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating for the company in a report on Thursday, September 24th. Finally, Barclays boosted their target price on shares of Tandem Diabetes Care from $18.00 to $20.00 and gave the company an “equal weight” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $27.18.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem’s product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.